Arpeet Shah, MD

Panelists discuss how the future of IsoPSA and similar biomarkers depends on data validation, payer support, and integration into clinical guidelines.

Panelists discuss how IsoPSA strengthens biopsy discussions by providing objective data that supports patient confidence in shared decision-making.

In determining the best treatment, urologist Arpeet Shah, MD, stresses the importance of thorough diagnostics.

Panelists discuss how IsoPSA shows promise for equitable diagnostic performance but requires ongoing evaluation to ensure benefits reach all populations.

Panelists discuss how provider education and system-level support are vital for overcoming adoption barriers and ensuring IsoPSA is effectively used in practice.

Panelists discuss how pairing IsoPSA with MRI strengthens risk assessment and supports more informed shared decision-making in prostate cancer care.

Panelists discuss how IsoPSA strengthens diagnostic certainty by addressing gaps in MRI performance, offering a more reliable basis for biopsy decisions.

Panelists discuss how IsoPSA’s long-term predictive performance supports safer follow-up strategies and greater confidence in risk-based management.

Panelists discuss how real-world evidence confirms IsoPSA’s predictive value, showing that high scores align with significantly greater long-term cancer risk.

Panelists discuss how IsoPSA improves diagnostic accuracy by targeting PSA protein structure, offering clearer insights for patient selection than concentration-based testing.

Panelists discuss how structure-based biomarkers such as IsoPSA improve risk stratification by distinguishing aggressive disease from indolent cases more effectively than PSA level alone.

Arpeet Shah, MD, highlights the shift toward precision medicine, ongoing work force challenges, the integration of AI, and more.